Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

STATUS

Recruiting
participants needed

70
sponsor

AIO-Studien-gGmbH

Send

Updated on 19 February 2024

See if I qualify

cancer

HIV Infection

metastasis

atezolizumab

carboplatin

neutrophil count

lung cancer

liver metastasis

heart failure

solid organ transplant

antiretroviral therapy

etoposide

immunosuppressive

brain metastases

major surgery

ipilimumab

myocardial infarction

steroid therapy

corticosteroid therapy

systemic therapy

tuberculosis

autoimmune disease

dementia

systemic disease

unstable angina

angina pectoris

immunodeficiency

aptt

pd-l1

congestive heart failure

cns metastases

cerebrovascular disease

immunosuppressant

cardiac arrhythmia

brain metastasis

neuroendocrine tumor

non-small cell lung cancer

small cell lung cancer

extensive stage sclc

Summary

Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver and brain.

Compared with non-small-cell lung cancer (NSCLC) SCLC has a unique natural history with a shorter doubling time, higher growth fraction, earlier development of widespread metastases, and uniform initial response to chemo- or radiotherapy.

The combination of cis- or carboplatin and etoposide is the standard of care in the first-line treatment of stage IV (extensive-disease) SCLC (ED-SCLC). Despite response rates of 50-80%, most patients relapse within six months and the median survival time is less than 10 months. Between 14 and 23% of SCLC patients develop brain metastases.

New cytotoxic agents as well as targeted therapies have not been able to show any improvement of survival in this group of patients.

Early phase trials of PD 1/PD L1-blocking immunotherapeutic agents in patients with recurrent or ED SCLC have shown promising response rates and good tolerability. Immunotherapy may also contribute to the efficacy of systemic treatment by maintaining initial responses to chemotherapy. A double-blind, placebo-controlled phase 3 trial indicates that the addition of atezolizumab to standard chemotherapy significantly improves overall survival and progression-free survival compared with chemotherapy alone in treatment-nave patients with ED-SCLC who are in good general condition (ECOG 0 or 1). However, about one in three SCLC patients has a poor performance status (ECOG2), which is associated with even shorter survival times of under eight months. At present, there is little information regarding the feasibility, safety and efficacy of adding atezolizumab to standard chemotherapy for this considerable fraction of patients.

The investigators expect, that atezolizumab in addition to chemotherapy is feasible in patients with stage IV SCLC and reduced performance status and therefore crucial efficacy data can be acquired in this trial to evaluate a putative Phase III transition in this particular patient population.

Details

Condition	SCLC, Extensive Stage
Age	18-100 years
Treatment	Atezolizumab
Clinical Study Identifier	NCT04221529
Sponsor	AIO-Studien-gGmbH
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Written informed consent including participation in translational research obtained from the subject prior to performing any protocol-related procedures, including screening evaluations that are not SOC
	ECOG 2
	At least one measurable tumor lesion (according to RECIST1.1)
	Histologically confirmed small cell lung cancer (SCLC)
	Stage IV disease (according to UICC8)
	No active autoimmune disease
	Adequate organ function defined as
	neutrophil count > 1.5 x 109/L
	thrombocytes 100 x 109/L
	hemoglobin 9 g/dL
	INR 1.4 or aPTT 40 sec during the last 7 days before therapy [Subjects under therapeutic anticoagulation are permitted.]
	bilirubin < 1.5 x ULN
	AST (SGOT)/ALT (SGPT) < 3 x institutional ULN (< 5 x ULN in case of liver metastases)
	creatinine 1.5 x ULN or creatinine clearance 45 mL/min
	Availability of tumor tissue/block
	Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the first dose of IMP
	Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. [WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of IMP.]
	Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving IMP and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 6 months after the last dose of IMP. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) and men who are azoospermic do not require contraception
	Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up
Exclusion Criteria
	Any preceding systemic anticancer therapy for stage IV SCLC. [Up to one full-cycle-dosing of carboplatin+etoposide chemotherapy within the context of SOC is permitted prior to study treatment.] (Note: Prior treatment for limited stage disease allowed)
	Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lives of previously used trial medication, whichever is longer
	Prior therapy with an anti-Programmed cell death protein 1 (anti-PD-1), anti-Programmed cell death-ligand 1 (anti-PD-L1), anti-Programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor [TNFR] family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
	Previous treatment in the present study (does not include screening failure)
	Symptomatic CNS metastases. [Patients with asymptomatic brain metastases may be included.]
	Major surgery 28 days before first dose of study treatment
	Any uncontrolled systemic disease, condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to
	known active HBV, HCV or HIV infection [Patients who are HIV-positive are allowed in the trial, so long as they are stable on anti-retroviral therapy, have a CD4 count 200 cells/L, and have an undetectable viral load at the time of screening.]
	active tuberculosis
	any other active infection requiring systemic therapy
	history of allogeneic tissue/solid organ transplant
	diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of IMP
	other active malignancy requiring treatment
	clinically significant or symptomatic cardiovascular/cerebrovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before enrolment
	Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year)
	Known hypersensitivity to carboplatin, etoposide or atezolizumab or any of the constituents of the product
	Medication that is known to interfere with any of the agents applied in the trial
	Any condition or disease which might interfere with the subject's ability to comply with the study procedures (e.g., dementia)
	Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities [ 40 Abs. 1 S. 3 Nr. 4 AMG]
	Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [ 40 Abs. 1 S. 3 Nr. 3a AMG]

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

solid organ transplant

antiretroviral therapy

myocardial infarction

steroid therapy

corticosteroid therapy

congestive heart failure

cns metastases

cerebrovascular disease

non-small cell lung cancer

small cell lung cancer

extensive stage sclc

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide